Yahoo Finance • 5 months ago
Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with significant debt, as per a Financial Times... Full story
Yahoo Finance • 7 months ago
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday? Tech stocks soared to their best session in five months on Wednesday, ahead of t... Full story
Yahoo Finance • last year
Key Insights Using the 2 Stage Free Cash Flow to Equity, Bausch + Lomb fair value estimate is US$25.50 Current share price of US$15.64 suggests Bausch + Lomb is potentially 39% undervalued The US$20.58 analyst price target for BLCO is 19%... Full story
Yahoo Finance • 2 years ago
Bausch + Lomb Corporation (NYSE: BLCO) has acquired Johnson & Johnson's (NYSE: JNJ) eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC) consumer products for eye care. The deal marks... Full story
Yahoo Finance • 2 years ago
Eye-care company Bausch + Lomb Corp. named Brent Saunders as chief executive officer and chairman of its board. Mr. Saunders will succeed Joseph Papa, who had said last July that he would step down from his roles running the company and se... Full story